92 related articles for article (PubMed ID: 27765510)
21. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
[TBL] [Abstract][Full Text] [Related]
22. 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.
Cano C; Saravanan K; Bailey C; Bardos J; Curtin NJ; Frigerio M; Golding BT; Hardcastle IR; Hummersone MG; Menear KA; Newell DR; Richardson CJ; Shea K; Smith GC; Thommes P; Ting A; Griffin RJ
J Med Chem; 2013 Aug; 56(16):6386-401. PubMed ID: 23855836
[TBL] [Abstract][Full Text] [Related]
23. The pyrrolidinoindoline alkaloid Psm2 inhibits platelet aggregation and thrombus formation by affecting PI3K/Akt signaling.
Su XL; Su W; Wang Y; Wang YH; Ming X; Kong Y
Acta Pharmacol Sin; 2016 Sep; 37(9):1208-17. PubMed ID: 27424653
[TBL] [Abstract][Full Text] [Related]
24. 1,4-Benzoxazine-3(4H)-ones as potent inhibitors of platelet aggregation: design, synthesis and structure-activity relations.
Liu C; Tan JL; Xiao SY; Liao JF; Zou GR; Ai XX; Chen JB; Xiang Y; Yang Q; Zuo H
Chem Pharm Bull (Tokyo); 2014; 62(9):915-20. PubMed ID: 25007750
[TBL] [Abstract][Full Text] [Related]
25. Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922).
Zheng Z; Pinson JA; Mountford SJ; Orive S; Schoenwaelder SM; Shackleford D; Powell A; Nelson EM; Hamilton JR; Jackson SP; Jennings IG; Thompson PE
Eur J Med Chem; 2016 Oct; 122():339-351. PubMed ID: 27387421
[TBL] [Abstract][Full Text] [Related]
26. The synthesis and biological evaluation of nucleobases/tetrazole hybrid compounds: A new class of phosphodiesterase type 3 (PDE3) inhibitors.
Shekouhy M; Karimian S; Moaddeli A; Faghih Z; Delshad Y; Khalafi-Nezhad A
Bioorg Med Chem; 2020 Jun; 28(12):115540. PubMed ID: 32503691
[TBL] [Abstract][Full Text] [Related]
27. Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK).
Cano C; Golding BT; Haggerty K; Hardcastle IR; Peacock M; Griffin RJ
Org Biomol Chem; 2010 Apr; 8(8):1922-8. PubMed ID: 20449499
[TBL] [Abstract][Full Text] [Related]
28. 1,2-fused pyrimidines. VI. Substituted 2-amino-4H-pyrido[1,2-a]pyrimidin-4-ones with antiplatelet activity.
Roma G; Di Braccio M; Leoncini G; Aprile B
Farmaco; 1993 Sep; 48(9):1225-38. PubMed ID: 8259980
[TBL] [Abstract][Full Text] [Related]
29. Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
El-Damasy AK; Cho NC; Pae AN; Kim EE; Keum G
Bioorg Med Chem Lett; 2016 Jul; 26(14):3307-3312. PubMed ID: 27241691
[TBL] [Abstract][Full Text] [Related]
30. Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives.
Clapham KM; Rennison T; Jones G; Craven F; Bardos J; Golding BT; Griffin RJ; Haggerty K; Hardcastle IR; Thommes P; Ting A; Cano C
Org Biomol Chem; 2012 Sep; 10(33):6747-57. PubMed ID: 22814419
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of 4,5-functionalized-2-methyl-6-(substituted aryl)-3 (2H)-pyridazinones: a new group of potent platelet aggregation inhibitors.
Dal Piaz V; Ciciani G; Giovannoni MP
Farmaco; 1997 Mar; 52(3):173-8. PubMed ID: 9212451
[TBL] [Abstract][Full Text] [Related]
32. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
[TBL] [Abstract][Full Text] [Related]
33. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity.
Wang WY; Hsieh PW; Wu YC; Wu CC
Biochem Pharmacol; 2007 Aug; 74(4):601-11. PubMed ID: 17601492
[TBL] [Abstract][Full Text] [Related]
35. Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
Duan LM; Yu HY; Li YL; Jia CJ
Bioorg Med Chem; 2015 Sep; 23(18):6111-7. PubMed ID: 26319621
[TBL] [Abstract][Full Text] [Related]
36. Cilostazol Induces PGI2 Production via Activation of the Downstream Epac-1/Rap1 Signaling Cascade to Increase Intracellular Calcium by PLCε and to Activate p44/42 MAPK in Human Aortic Endothelial Cells.
Hashimoto A; Tanaka M; Takeda S; Ito H; Nagano K
PLoS One; 2015; 10(7):e0132835. PubMed ID: 26181635
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and inhibitory activities on platelet aggregation of some flavonoid analogues.
Göker H; Tunçbilek M; Leoncini G; Buzzi E; Mazzei M; Rolland Y; Ertan R
Arzneimittelforschung; 1995 Feb; 45(2):150-5. PubMed ID: 7710437
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.
Barlaam B; Cosulich S; Degorce S; Fitzek M; Green S; Hancox U; Lambert-van der Brempt C; Lohmann JJ; Maudet M; Morgentin R; Péru A; Plé P; Saleh T; Ward L; Warin N
Bioorg Med Chem Lett; 2016 May; 26(9):2318-23. PubMed ID: 26996374
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.
Ochiai K; Takita S; Kojima A; Eiraku T; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2013 Jan; 23(1):375-81. PubMed ID: 23200255
[TBL] [Abstract][Full Text] [Related]
40. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
